Dopamine receptor ligands and imaging agents
CA 2011738 C · Owner: The Trustees Of The University Of Pennsylvania · Inventors: Kung, Hank F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel CNS dopamine D-1 receptors, such as the compound ()-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-(4'-125Iiodophenyl)- 1H-3-benzazepine-7-ol, are disclosed. These compounds are useful as imaging agents for D-1 receptors in the human brain and exhibit good brain retention and in vivo stability. The invention also extends to a process for preparing the novel compounds and to, novel intermediates useful in the preparation of the novel compounds.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 8, 1990 and granted March 18, 1997. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 8, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 8, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.